Jason Throne - 03 Nov 2023 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Role
Chief Legal Officer
Signature
/s/ Jason Throne
Issuer symbol
IDYA
Transactions as of
03 Nov 2023
Net transactions value
-$88,964
Form type
4
Filing time
07 Nov 2023, 17:47:40 UTC
Previous filing
14 Sep 2023
Next filing
19 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDYA Common Stock Options Exercise $66,396 +5,163 $12.86 5,163 03 Nov 2023 Direct
transaction IDYA Common Stock Sale $155,360 -5,163 -100% $30.09 0 03 Nov 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDYA Stock Option (Right to Buy) Options Exercise $0 -5,163 -9.6% $0.000000 48,750 03 Nov 2023 Common Stock 5,163 $12.86 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 29, 2023.
F2 This transaction was executed in multiple trades in prices ranging from $30.00 to $30.23, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.